OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
HERO$392.0055

DFI Retail Nusantara Tbk Pt

Food Retail & DistributionVerified

DFI Retail Nusantara Tbk Pt has a market price of 392.0, with a market capitalization of 1,639,984,528,000.0. The company's price-to-earnings ratio is 10.04, and its price-to-book ratio is 0.98, indicating a valuation that is in line with book value. The company's liquidity is assessed as medium, with a current ratio of 0.46, suggesting that it may face challenges in meeting short-term obligations. The company's debt-to-equity ratio is 1.16, indicating a moderate level of leverage. In terms of profitability, the company's return on equity is 0.098, and its return on assets is 0.034, which are below the industry median for the Food Retail & Distribution sector. The company's operating margin is 11.41%, and its net profit margin is 16.38%, which are also below the industry median. The company's gross profit margin is 41.99%, which is in line with the industry median. DFI Retail Nusantara Tbk Pt's revenue is primarily concentrated in Indonesia, with no significant international exposure. The company's revenue is not disclosed by segment, but it is known to operate in the food and drug retailing sector. The company's revenue concentration is high, with no diversification across multiple markets or product lines. The company's growth trajectory is expected to be moderate, with a revenue outlook that is in line with the industry median. The company's capital expenditure is -53,540,000,000.0, indicating a reduction in investment in physical assets. The company's free cash flow is 124,494,000,000.0, which is a positive indicator of its ability to generate cash. The company's risk assessment indicates a medium level of liquidity risk, with a current ratio of 0.46. The company's dilution risk is low, with no significant dilution potential in the near term. The company's key flags include a negative net cash position after subtracting total debt, which may impact its financial flexibility. Recent events for the company include the publication of its latest financial data, which shows a revenue of 996,963,000,000.0 and a net income of 163,289,000,000.0. The company has not disclosed any significant recent events or filings that would impact its financial position or strategic direction.

30-day price · HERO+44.00 (+10.9%)
Low$378.00High$730.00Close$448.00As of13 May, 00:00 UTC
Profile
CompanyDFI Retail Nusantara Tbk Pt
TickerHERO.JK
SectorConsumer Non-Cyclicals
BusinessFood & Drug Retailing
Industry groupFood & Drug Retailing
IndustryFood Retail & Distribution
AI analysis

Business. DFI Retail Nusantara Tbk Pt operates as a food and drug retailer in Indonesia, generating revenue primarily through the sale of groceries, household goods, and pharmaceutical products.

Classification. The company is classified under the Consumer Non-Cyclicals economic sector, specifically in the Food & Drug Retailing business sector, with a high confidence level of 0.92.

DFI Retail Nusantara Tbk Pt has a market price of 392.0, with a market capitalization of 1,639,984,528,000.0. The company's price-to-earnings ratio is 10.04, and its price-to-book ratio is 0.98, indicating a valuation that is in line with book value. The company's liquidity is assessed as medium, with a current ratio of 0.46, suggesting that it may face challenges in meeting short-term obligations. The company's debt-to-equity ratio is 1.16, indicating a moderate level of leverage. In terms of profitability, the company's return on equity is 0.098, and its return on assets is 0.034, which are below the industry median for the Food Retail & Distribution sector. The company's operating margin is 11.41%, and its net profit margin is 16.38%, which are also below the industry median. The company's gross profit margin is 41.99%, which is in line with the industry median. DFI Retail Nusantara Tbk Pt's revenue is primarily concentrated in Indonesia, with no significant international exposure. The company's revenue is not disclosed by segment, but it is known to operate in the food and drug retailing sector. The company's revenue concentration is high, with no diversification across multiple markets or product lines. The company's growth trajectory is expected to be moderate, with a revenue outlook that is in line with the industry median. The company's capital expenditure is -53,540,000,000.0, indicating a reduction in investment in physical assets. The company's free cash flow is 124,494,000,000.0, which is a positive indicator of its ability to generate cash. The company's risk assessment indicates a medium level of liquidity risk, with a current ratio of 0.46. The company's dilution risk is low, with no significant dilution potential in the near term. The company's key flags include a negative net cash position after subtracting total debt, which may impact its financial flexibility. Recent events for the company include the publication of its latest financial data, which shows a revenue of 996,963,000,000.0 and a net income of 163,289,000,000.0. The company has not disclosed any significant recent events or filings that would impact its financial position or strategic direction.
Key takeaways
  • The company's valuation is in line with book value, with a price-to-book ratio of 0.98.
  • The company's liquidity is assessed as medium, with a current ratio of 0.46.
  • The company's profitability is below the industry median, with a return on equity of 0.098.
  • The company's revenue is concentrated in Indonesia, with no significant international exposure.
  • The company's growth trajectory is expected to be moderate, with a revenue outlook in line with the industry median.
  • The company's risk assessment indicates a low level of dilution risk and a medium level of liquidity risk.
  • --
  • ## RATIONALES
Financial snapshot
PeriodHA-latest
CurrencyIDR
Revenue$996.96B
Gross profit$418.79B
Operating income$113.80B
Net income$163.29B
R&D
SG&A
D&A
SBC
Operating cash flow$71.10B
CapEx-$53.54B
Free cash flow$124.49B
Total assets$4.81T
Total liabilities$3.14T
Total equity$1.67T
Cash & equivalents
Long-term debt$1.94T
Annual history (last 5)
PeriodRevenueOp IncomeNet IncomeFCF
FY-4$3.48T-$548.96B-$963.53B-$615.35B
FY-3$4.44T-$19.77B$59.11B-$258.24B
FY-2$4.39T-$105.23B-$132.16B-$280.20B
FY-1$4.54T$72.96B-$5.58B$56.40B
FY0$4.85T$94.25B$160.34B$262.73B
PeriodGross %Op %Net %FCF %
FY-4
FY-3
FY-2
FY-1
FY0
PeriodAssetsEquityCashDebt
FY-4$6.27T$873.82B
FY-3$6.91T$938.14B
FY-2$5.77T$1.42T
FY-1$4.72T$1.49T$74.25B
FY0$4.42T$1.66T$0.00
PeriodOCFCapExFCFSBC
FY-4-$661.68B-$463.48B-$615.35B
FY-3-$692.47B-$274.54B-$258.24B
FY-2$260.26B-$191.12B-$280.20B
FY-1$333.97B-$133.42B$56.40B
FY0$568.02B-$119.41B$262.73B
Quarterly history (last 4)
PeriodRevenueOp IncomeNet IncomeFCF
FQ-7$996.96B$113.80B$163.29B$124.49B
FQ-6$1.13T$61.94B$21.48B$92.10B
FQ-5$1.16T-$115.36B-$189.23B-$136.22B
FQ-4$1.21T$68.93B$27.14B$70.52B
FQ-3$1.14T$66.63B$48.04B$100.92B
FQ-2$1.16T$27.09B-$4.84B$32.62B
FQ-1$1.34T-$68.40B$90.00B$61.94B
FQ0$1.41T$63.27B$87.02B$72.65B
PeriodGross %Op %Net %FCF %
FQ-7
FQ-6
FQ-5
FQ-4
FQ-3
FQ-2
FQ-1
FQ0
PeriodAssetsEquityCashDebt
FQ-7$4.81T$1.67T
FQ-6$4.76T$1.68T
FQ-5$4.72T$1.49T$74.25B
FQ-4$4.78T$1.52T$18.63B
FQ-3$4.50T$1.57T
FQ-2$4.49T$1.56T
FQ-1$4.42T$1.66T$0.00
FQ0$4.31T$1.75T
PeriodOCFCapExFCFSBC
FQ-7$71.10B-$53.54B$124.49B
FQ-6$44.85B-$76.59B$92.10B
FQ-5$333.97B-$133.42B-$136.22B
FQ-4$52.14B-$28.41B$70.52B
FQ-3$92.86B-$53.73B$100.92B
FQ-2$311.64B-$90.88B$32.62B
FQ-1$568.02B-$119.41B$61.94B
FQ0-$14.23B-$66.61B$72.65B
Valuation
Market price$392.00
Market cap$1.64T
Enterprise value$3.58T
P/E10.0
Reported non-GAAP P/E
EV/Revenue3.6
EV/Op income31.5
EV/OCF50.4
P/B1.0
P/Tangible book1.0
Tangible book$1.67T
Net cash-$1.94T
Current ratio0.5
Debt/Equity1.2
ROA3.4%
ROE9.8%
Cash conversion44.0%
CapEx/Revenue-5.4%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskMedium
  • Net cash is negative after subtracting total debt.
Industry benchmarks
Activity: Food & Drug Retailing · cohort 184 companies
MetricHEROActivity
Op margin11.4%3.1% medp25 1.2% · p75 6.8%top quartile
Net margin16.4%2.0% medp25 0.7% · p75 4.1%top quartile
Gross margin42.0%26.1% medp25 17.2% · p75 32.0%top quartile
CapEx / revenue-5.4%-2.5% medp25 -4.6% · p75 -1.4%bottom quartile
Debt / equity116.0%56.0% medp25 16.8% · p75 121.1%above median
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod FQ-7 · history via verified-market-data
no public URL
2026-05-10 10:38 UTC#a9f0c896
Market quoteclose IDR 478.00 · shares 4.18B diluted
no public URL
2026-05-10 10:38 UTC#7f72606b
Source: analysis-pipeline (hybrid)Generated: 2026-05-28 02:55 UTCJob: 741d874b